Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Gastroenterology Année : 2015

Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

Gregory Dore
  • Fonction : Auteur
Eric Lawitz
  • Fonction : Auteur
  • PersonId : 1027564
Alnoor Ramji
  • Fonction : Auteur
Harvey Tatum
  • Fonction : Auteur
Gloria Taliani
  • Fonction : Auteur
Maurizia Brunetto
  • Fonction : Auteur
  • PersonId : 880506
Serena Zaltron
  • Fonction : Auteur
Simone Strasser
  • Fonction : Auteur
Nina Weis
  • Fonction : Auteur
  • PersonId : 895851
Wayne Ghesquiere
  • Fonction : Auteur
Samuel Lee
  • Fonction : Auteur
Hugh Harley
  • Fonction : Auteur
Jacob George
Scott Fung
  • Fonction : Auteur
Peggy Hagens
  • Fonction : Auteur
Fiona Mcphee
  • Fonction : Auteur
Dennis Hernandez
  • Fonction : Auteur
David Cohen
Elizabeth Cooney
  • Fonction : Auteur
Stephanie Noviello
  • Fonction : Auteur
Eric Hughes
  • Fonction : Auteur

Résumé

BACKGROUND & AIMS: Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. METHODS: Patients with HCV genotype 2 or 3 infection (n = 151), enrolled at research centers in North America, Europe, or Australia, were assigned randomly to groups given 12 or 16 weeks of daclatasvir (60 mg once daily), or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin. Treatment was extended to 24 weeks for recipients of daclatasvir who did not meet the criteria for early virologic response. The primary end point was SVR at 24 weeks after treatment (SVR24). RESULTS: Baseline characteristics were similar among patients within each HCV genotype group. However, the 80 patients with HCV genotype 3, compared with the 71 patients with HCV genotype 2, were younger (mean age, 45 vs 53 y, respectively), and a larger proportion had cirrhosis (23% vs 1%, respectively). Among patients with HCV genotype 2 infection, an SVR24 was achieved by 83%, 83%, and 63% of those in the daclatasvir 12-week group, the daclatasvir 16-week group, or the placebo group, respectively; among patients with HCV genotype 3 infection, an SVR24 was achieved by 69%, 67%, and 59% of patients in these groups, respectively. Differences between genotypes largely were attributable to the higher frequency of post-treatment relapse among patients infected with HCV genotype 3. In both daclatasvir arms for both HCV genotypes, the lower bound of the 80% confidence interval of the difference in SVR24 rates between the daclatasvir and placebo arms was above -20%, establishing noninferiority. Safety findings were similar among groups, and were typical of those expected from peginterferon alfa and ribavirin therapy. CONCLUSIONS: Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Clinicaltrials.gov number: NCT01257204.
Fichier non déposé

Dates et versions

hal-02271960 , version 1 (27-08-2019)

Identifiants

Citer

Gregory Dore, Eric Lawitz, Christophe Hézode, Stephen Shafran, Alnoor Ramji, et al.. Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection. Gastroenterology, 2015, 148 (2), pp.355-366.e1. ⟨10.1053/j.gastro.2014.10.007⟩. ⟨hal-02271960⟩
57 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More